达比加群酯联合塞来昔布致上消化道出血1例
发布时间：2018-08-31 18:55
【摘要】：正达比加群酯(dabigatran etexilate)是一种新型口服抗凝药物(NOACs),2010年获得美国食品和药物管理局(FDA)批准用于预防非瓣膜性房颤患者卒中和全身性栓塞,2013年在中国上市~([1])。达比加群酯是前体药物,口服后经酯酶水解释放出活性成分达比加群而发挥抗凝作用。虽然达比加群酯属于直接凝血酶抑制剂,具有靶点单一、安全性好,无需特殊用药监测等优势,有望取代华法
[Abstract]:(dabigatran etexilate) is a new oral anticoagulant drug, which was approved by the US Food and Drug Administration (FDA) in 2010 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation. It was listed in China in 2013. Darbine-group ester is a precursor drug, which is released by esterase hydrolysis to play an anticoagulant effect. Although Darby + group ester is a direct thrombin inhibitor with single target, good safety and no need for special drug monitoring, it is expected to replace the Chinese method.
【作者单位】： 南昌大学第二附属医院药学部;南昌大学第二附属医院心血管内科;
【基金】：“十二五”计划国家科技重大专项课题“心血管疾病抗凝药物临床评价技术平台建设”(2014ZX09303305)
【分类号】：R573.2
，
本文编号：2215865
[Abstract]:(dabigatran etexilate) is a new oral anticoagulant drug, which was approved by the US Food and Drug Administration (FDA) in 2010 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation. It was listed in China in 2013. Darbine-group ester is a precursor drug, which is released by esterase hydrolysis to play an anticoagulant effect. Although Darby + group ester is a direct thrombin inhibitor with single target, good safety and no need for special drug monitoring, it is expected to replace the Chinese method.
【作者单位】： 南昌大学第二附属医院药学部;南昌大学第二附属医院心血管内科;
【基金】：“十二五”计划国家科技重大专项课题“心血管疾病抗凝药物临床评价技术平台建设”(2014ZX09303305)
【分类号】：R573.2
，
本文编号：2215865
本文链接：https://www.wllwen.com/yixuelunwen/xiaohjib/2215865.html
最近更新
教材专著
